The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | IciCLLe extension: ibrutinib and obinutuzumab for clears MRD in R/R CLL
The IciCLLe study (ISRCTN12695354), part of the Bloodwise Trials Acceleration Programme (TAP), explored the use of ibrutinib in chronic lymphocytic leukemia (CLL). As part of the study’s extension, relapsed/refractory patients were given ibrutinib with obinutuzumab. We spoke to Talha Munir, MBBS, of Leeds Teaching Hospitals NHS Trust, Leeds, UK, about this extension at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Munir highlights the improved MRD response rates for patients 1-year or more post-treatment, and explains how combining the two drugs worked better in the second-line setting.
